The anatomic pathology market is projected to reach USD 49.1 billion by 2026 from USD 35.1 billion in 2021, at a CAGR of 7.0%. The growth of the anatomic pathology market is majorly driven by the high incidence of cancer and other target diseases, recommendations for cancer screening, availability of reimbursement, and the growing focus on personalized medicine. In addition, emerging economies such as China, India, and Brazil are expected to offer significant growth opportunities for players operating in the anatomic pathology market during the forecast period.
The anatomic pathology services segment accounted for the highest growth rate in the anatomic pathology market, by product and service, during the forecast period Based on product & service, the anatomic pathology market is segmented into services, consumables, and instruments.The anatomic pathology services segment is projected to register the highest CAGR during the forecast period.
The growth of this segment is primarily driven by rapid growing geriatric population and the increasing incidence of cancer and other chronic diseases.
Disease Diagnostics accounted for the highest CAGR Based on application, the anatomic pathology market is segmented into disease diagnostics and medical research.The disease diagnostics segment is projected to register the highest CAGR during the forecast period.
This can be attributed to rising geriatric population and the increasing incidence of cancer and other chronic diseases.
Hospital laboratories accounted for the highest CAGR Based on end user, the anatomic pathology market is segmented into hospital laboratories, clinical laboratories, and other end users.Hospital laboratories is projected to register the highest CAGR during the forecast period.
Increasing number of patient visits to hospitals, the growing number of in-house diagnostic procedures performed in hospitals, and growing awareness regarding early disease diagnosis are major factors contributing to growth of the segment.
Asia Pacific: The fastest-growing region in the Anatomic pathology market The anatomic pathology market is segmented into North America, Europe, Asia Pacific, and Rest of the World.The Asia Pacific region offers high-growth opportunities for players in the anatomic pathology market.
The presence of emerging economies like China and India, the large population in APAC countries, rising prevalence of chronic diseases, improving standard of living, growing demand for quality medical care, increasing healthcare spending and government initiatives, and rising awareness about the use of anatomic pathology tests among physicians are the major factors driving market growth in the Asia Pacific region.
The primary interviews conducted for this report can be categorized as follows: • By Company Type: Tier 1 - 28%, Tier 2 - 42%, and Tier 3 - 30% • By Designation: C-level - 30%, D-level - 34%, and Others - 36% • By Region: North America- 46%, Europe- 25%, Asia Pacific – 18%, RoW – 11%
Lists of Companies Profiled in the Report: • F. Hoffmann-La Roche Ltd. (Switzerland) • Danaher Corporation (US) • PHC Holdings Corporation (Japan) • Becton, Dickinson and Company (US) • Abcam plc (UK) • Agilent Technologies, Inc. (US) • Hologic, Inc. (US) • Merck KGaA (Germany) • Bio SB (US) • Diapath S.p.A. (Italy) • Histo-Line Laboratories (Italy) • Milestone Medical (Italy) • SLEE medical GmbH (Germany) • BioGenex (US) • Sakura Finetek (US) • Amos Scientific Pty Ltd. (Australia) • MEDITE Medical GmbH (Germany) • Cell Signaling Technology, Inc. (US) • CellPath Ltd. (UK) • Jinhua Yidi Medical Equipment Co., Ltd. (China) • MICROS AUSTRIA (Austria) • R. K. SCIENTIFIC INSTRUMENT PRIVATE LIMITED (India) • Lupetec (Brazil) • Medimeas (India) • Bright Instruments (UK)
Research Coverage: This report provides a detailed picture of the anatomic pathology market.It aims at estimating the size and future growth potential of the market across different segments, such as product & service, application, end user, and region.
The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall anatomic pathology market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.
This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, opportunities, challenges, and trends.
Our reports have been used by over 10K customers, including:
The anatomic pathology market is projected to reach US$ 33,145.78 million by 2028 from US$ 21,488. 41 million in 2021; it is estimated to grow at a CAGR of 6.4% from 2021 to 2028. Factors such as increase in the prevalence of cancer and other diseases, and growing focus on personalized medicines. However, the lack of skilled professionals...
269 pages •
By The Business Research Company
• Aug 2021
Anatomic Pathology Equipment and Consumables Market Opportunities And Strategies To 2030: COVID-19 Growth And Change provides the strategists, marketers and senior management with the critical information they need to assess the global anatomic pathology equipment and consumables market as it emerges from the COVID 19 shut down. Description: Where...
The human microbiome market is expected to reach US$ 2,921.68 million by 2028 from US$ 718.95 million in 2021; it is estimated to grow at a CAGR of 22.2% during 2021-2028. The market growth is mainly attributed to factors such as the increasing incidence of lifestyle diseases, rising focus on human microbiome therapies, and growing...
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected...
The Asia Pacific organoids market is expected to reach US$ 513.74 million in 2027 from US$ 97.02 million in 2019. The market is estimated to grow at a CAGR of 23.1% from 2020 to 2027. Rising adoption of biobanking and tumor modelling and alternatives for animal testing models acting as kingpins are expected to augment the growth of the...
The global organoids market is expected to reach US$ 3,420.40 million by 2027 from US$ 689.47 million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. Increasing demand for tumor modelling and biobanking, rising adoption of personalized drugs, and growing focus on developing alternatives for animal testing...
An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and airflow in organs, such as the lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional...
The global human microbiome market is expected to reach US$ 1,873.53 million by 2027 from US$ 356.29 million in 2019. The market is estimated to grow with a CAGR of 23.6% from 2020 to 2027. The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies,...
Executive Summary The global radiation therapy market was valued at USD 5216.04 million in the year 2019, according to a research report published in June 2020. The growth of the radiation therapy market will primarily be supported by an Increasing public health spending as cancer is the second most deadly disease in the...
Certain factors that are driving the market growth include the increased incidence of cancer, globally, and higher acceptance of treatments for cancer in the developing regions, the paradigm shift in healthcare, from disease diagnosis to risk assessment or early diagnosis, and increasing usage of biomarkers in drug development. - Globally,...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.